Read PPTA's 2025 Mid-Year Impact Report here.
July 17, 2025
by Marios Georgiou, Communications and Advocacy Manager
PPTA and its members have made significant progress on strategic priorities in Europe, the United States, and globally during the first half of 2025.
In the United States, the Plasma Caucus has grown from 26 to 40 bipartisan members, strengthening advocacy efforts on Capitol Hill. This includes meetings with 40 members of Congress during the May fly-in event. In Louisiana, the signing of HB 115 is a positive step towards simplifying the licensing of donation centers.
In Europe, PPTA intensified its engagement with EU institutions and national authorities. The Association participated in discussions regarding the implementation of the SoHO Regulation, provided input for the upcoming Critical Medicines Act, and took part in regulatory forums such as the EDQM Blood Conference and EMA workshops.Additionally, PPTA met with the office of EU Commission President Ursula von der Leyen to highlight the industry's strong manufacturing presence in Europe and emphasize the necessity for tailored, fit-for-purpose legislation for plasma-derived medicinal products (PDMPs).
This is just a brief summary ofwhat the Association and its members have achieved thus far – more information is detailed in the pages of the report. As you’ll see, despite an evolving world, PPTA remains dedicated to protecting access to plasma-derived therapies worldwide. “Many challenges — geopolitically in particular — will continue to impact the industry”, said Anita Brikman, PPTA President and CEO. “But our purpose remains the same: protecting and improving the lives of patients who rely on plasma-derived therapies.”
The Mid-Year Impact Report offers a detailed view of our work across regions and policy areas.
Click here to learn more.